ASH 2017
American Society of Hematology Annual Meeting
Interviews and expert commentary from ASH 2017 — study authors and key opinion leaders discuss the findings and their clinical implications.
Randomized Study Confirms Rivaroxaban Oral Alternative For Cancer Thromboembolism
ATLANTA—Six months follow up of the Select-D randomized open label multicenter pilot study with 406 patients has confirmed that therapy with the direct oral anticoagulant (DOAC) rivaroxaban was a safe
Rivaroxaban Confirmed as Oral Alternative For Cancer Thromboembolism
ATLANTA—Six months follow up of the Select-D randomized open label multicenter pilot study with 406 patients has confirmed that therapy with the direct oral anticoagulant (DOAC) rivaroxaban was a safe
Oral Anticoagulant Edoxaban Alternative for Cancer-Related Thromboembolism
ATLANTA— In patients with a variety of cancers oral therapy with edoxaban—a direct oral anticoagulant (DOAC)—was just as effective and safe in terms of the risks of recurrent venous thromboembolism (V
Venetoclax Pro-Apoptotic Therapy Benefits Older Patients with Acute Myeloid Leukemia
ATLANTA—Adding anti-BCL-2 therapy with the small-molecule drug venetoclax (VEN) to standard low-dose cytarabine (LDAC) chemotherapy tripled response rates over historical comparators and extended surv
Subcutaneous Daratumumab “Potential Game Changer” for Multiple Myeloma
ATLANTA—Subcutaneous administration of the anti-CD 38 monoclonal antibody daratumumab could help more patients get this emerging therapy more easily for their advanced or recently-diagnosed multiple m